Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evotec AG ( (EVO) ) has provided an announcement.
On 16 January 2026, Evotec SE reported that it had submitted several Notifications of Major Holdings to the German financial regulator BaFin, reflecting changes in significant shareholdings in the company earlier in the month. The filings detail that The Goldman Sachs Group, Inc. crossed a disclosure threshold on 13 January 2026, with its total position in Evotec amounting to 6.12% of voting rights when including both directly held shares and financial instruments, up from a previously reported 3.68%. These notifications signal a strengthened financial exposure by a major institutional investor and provide updated transparency to the market regarding Evotec’s shareholder structure, which may be of interest to existing shareholders and potential investors monitoring shifts in the company’s ownership base.
The most recent analyst rating on (EVO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a Germany-based drug discovery and development company that operates as a research and development partner for the pharmaceutical and biotechnology industry, providing integrated discovery platforms, proprietary technologies and services to support the identification and development of new therapeutics across multiple disease areas.
Average Trading Volume: 134,637
Technical Sentiment Signal: Sell
Current Market Cap: $1.32B
For an in-depth examination of EVO stock, go to TipRanks’ Overview page.